Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,258.00GBp
23 Apr 2018
Change (% chg)

-- (--)
Prev Close
1,258.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
685,440
52-wk High
2,000.00
52-wk Low
814.20

Select another date:

Mon, Mar 12 2018

GSK wins new reprieve as Hikma's generic Advair delayed again

GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.

BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus

* HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE'S ADVAIR DISKUS

Hikma plans new clinical study over generic Advair

March 12 Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.

UPDATE 1-Drugmaker Hikma names former Teva exec Olafsson as CEO; shares up

Feb 20 Hikma Pharmaceuticals Plc named former Teva Pharmaceutical executive Sigurdur Olafsson as its CEO, as the Jordan-based drugmaker looks to improve its struggling generics business.

BRIEF-Hikma Pharmaceutical Names Sigurdur Olafsson As CEO

* SAYS OLAFSSON WILL ALSO JOIN HIKMA'S BOARD OF DIRECTORS AS AN EXECUTIVE DIRECTOR

Drugmaker Hikma appoints Sigurdur Olafsson as CEO

Feb 20 Drugmaker Hikma Pharmaceuticals Plc said on Tuesday it appointed Sigurdur Olafsson as its chief executive, effective immediately.

Hikma wins right to market Roche drug copy in Middle East and North Africa

Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

Hikma wins right to market Roche drug copy in Middle East and North Africa

Dec 19 Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

BRIEF-Hikma Pharmaceuticals ‍Reaches Licensing Agreement With Celltrion

* ‍REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA​

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

Select another date: